Ex does not understand the difference between clinical trial manufacturing and commercial manufacturing, or is counting on observers not to understand it. The former is often painstakingly inefficient. The latter, which in NWBO's case, started being developed in January 2014 by Cognate for eventual implementation upon approval, is more efficient and includes such things as round the clock production, tangential flow filtration, far more dedicated clean rooms and round the clock support for most/all contingencies. There is no comparison. He is jerking everyone around by the nose. Cogante has quadrupled its cleanroom and employee capacity and is expanding once again. Ex, on the other hand, is just playing everyone. Dendreon was not ready for commercial demand that might materialize and was in massive debt when Provenge was approved. NWBO's manufacturer, Cognate, is in just the opposite situation. If NWBO started with 25% of the market initially, it would have to produce about 12 batches per day on average. (Noting an eight day lead time, as any one batch takes seven to eight days to complete.)
Market Data 
Markets 
AI
